—
C+
C+ The full Closelook — membership. Open the C+ overview

Liquidia Technologies Inc (LQDA) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Liquidia Technologies Inc

LQDA in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Liquidia Technologies develops and sells therapies for rare heart-and-lung diseases, mainly pulmonary hypertension. Its lead product, Yutrepia, is an inhaled dry-powder form of treprostinil, and it also sells Remodulin, an injected version of the same drug given through a pump. It is developing L606, a liposomal formulation of treprostinil now in late-stage trials, and holds a particle-engineering platform called PRINT that shapes drug particles with precise control. The company is based in Morrisville, North Carolina.
Where it sits in the stack
Liquidia carries no seat in our Closelook index. It sits within the Healthcare sector of our universe, in the specialty and generic drug-manufacturing sleeve, outside the AI build-out stack tracked elsewhere in the diary.
Who it is priced against
Closelook's peer group has not been built for this name. The comparison the market often draws is with United Therapeutics, another maker of treprostinil-based therapies for pulmonary hypertension.
Why Closelook tracks it
Liquidia holds no index seat and no score in our system; the diary has not yet built coverage on it.
What the diary watches
The diary watches whether uptake of the inhaled treprostinil product can hold ground against established pulmonary-hypertension therapies as it scales.

Liquidia Technologies Inc (LQDA) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for LQDA, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 1 analyst action on the wire · latest: price target by Raymond James, 2026-08-13

The Street on this name

Analyst actions and the latest print for LQDA from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Raymond James — target 106 from 68 Target raised to $106 from $68 (+35.1% to spot) 2026-08-13

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Drug Manufacturers - Specialty & Generic · US · 8 names with week and year-to-date

Peer group

Drug Manufacturers - Specialty & Generic · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against LQDA on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What LQDA pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +9.3% in FY2025 29 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Liquidia Technologies Inc (LQDA)?

Liquidia Technologies Inc trades as LQDA on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is LQDA in a Closelook index?

Not currently — Liquidia Technologies Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does LQDA trade against its moving averages?

Pullback inside an uptrend stack: Trades -10.8% vs the 50-day and +29.4% vs the 200-day average, 26.9% below the 52-week high and +223.4% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Liquidia Technologies Inc do?

Liquidia Technologies develops and sells therapies for rare heart-and-lung diseases, mainly pulmonary hypertension. Its lead product, Yutrepia, is an inhaled dry-powder form of treprostinil, and it also sells Remodulin, an injected version of the same drug given through a pump. It is developing L606, a liposomal formulation of treprostinil now in late-stage trials, and holds a particle-engineering platform called PRINT that shapes drug particles with precise control. Closelook's peer group has not been built for this name. The comparison the market often draws is with United Therapeutics, another maker of treprostinil-based therapies for pulmonary hypertension.

Where does Liquidia Technologies Inc sit in the AI build-out?

Liquidia carries no seat in our Closelook index. It sits within the Healthcare sector of our universe, in the specialty and generic drug-manufacturing sleeve, outside the AI build-out stack tracked elsewhere in the diary. Liquidia holds no index seat and no score in our system; the diary has not yet built coverage on it.

Does Liquidia Technologies Inc pay a dividend?

No cash distribution shows in Liquidia Technologies Inc’s price series over the last three years. The share count rose 9.3% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Liquidia Technologies Inc recently?

The most recent analyst action on Liquidia Technologies Inc on the Closelook wire is a price target by Raymond James on 2026-08-13 (target 106 from 68). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for LQDA, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Drug Manufacturers - Specialty & Generic. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.